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Abstract: Cancer stem cells (CSCs) represent rare tumor cell populations capable of self-renewal, 
differentiation, and tumor initiation and are highly resistant to chemotherapy and radiotherapy. 
Thus, therapeutic approaches that can effectively target CSCs and tumor cells could be the key to 
efficient tumor treatment. In this study, we explored the function of SPHK1 in breast CSCs and non-
CSCs. We showed that RNAi-mediated knockdown of SPHK1 inhibited cell proliferation and 
induced apoptosis in both breast CSCs and non-CSCs, while ectopic expression of SPHK1 enhanced 
breast CSC survival and mammosphere forming efficiency. We identified STAT1 and IFN signaling 
as key regulatory targets of SPHK1 and demonstrated that an important mechanism by which 
SPHK1 promotes cancer cell survival is through the suppression of STAT1. We further 
demonstrated that SPHK1 inhibitors, FTY720 and PF543, synergized with doxorubicin in targeting 
both breast CSCs and non-CSCs. In conclusion, we provide important evidence that SPHK1 is a key 
regulator of cell survival and proliferation in breast CSCs and non-CSCs and is an attractive target 
for the design of future therapies. 
Keywords: cancer stem cells; sphingosine kinase; STAT1; mammospheres; drug synergism; 
sphingolipids 
 
1. Introduction 
Breast cancer stem cells (CSCs) represent a subset of cancer cells with the capabilities of self-
renewal and differentiation [1,2]. Although several signaling pathways (such as STAT3 [3,4], Wnt/β-
Catenin [5–7], Notch [8–11], Hedgehog [12–16], and NFB [17–19]) have been implicated in regulating 
the growth and survival of breast CSCs, designing selective CSC-targeted strategies using these 
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pathways remains a challenge as these pathways also share common functional roles in the 
maintenance of normal stem cells [20–23]. 
Sphingosine kinase (SPHK) catalyses the ATP-dependent phosphorylation of sphingosine to 
form sphingosine 1-phosphate (S1P), which acts as an intracellular second messenger and 
extracellular ligand for specific receptors [24–26]. S1P can be released through specific transporters 
to act as a ligand for the family of G protein-coupled S1P receptors 1 to 5 (S1P1 to S1P5) and regulates 
a wide range of biological effects including transformation and cancer cell survival [24]. S1P levels 
are tightly regulated by the balance between synthesis by SPHK, reversible conversion to sphingosine 
by specific S1P phosphatases (SPP1 and SPP2), and degradation by S1P lyase [27]. In contrast to S1P, 
which is associated with growth and survival, its precursors, sphingosine and ceramide, are 
associated with cell growth arrest and apoptosis [28]. According to the sphingolipid rheostat model, 
the balance between these interconvertible sphingolipids, ceramide, sphingosine, and S1P, regulates 
cellular growth and survival in response to cellular and environmental stimuli [29–33]. Thus, SPHK 
is a critical regulator of this rheostat, as it produces the pro-growth and anti-apoptotic S1P and also 
reduces levels of pro-apoptotic ceramide and sphingosine [26,30,34–37]. Thus, the inhibition of SPHK 
is likely to have an anti-cancer effect by producing apoptotic ceramide/sphingosine. 
There are two isoforms of sphingosine kinase called SPHK1 and SPHK2. Several studies have 
indicated that increased SPHK1 activity promotes cancer cell growth, metastasis, and inhibits 
apoptosis [24–26,38–41]. Indeed, high expression of SPHK1 in tumors is associated with worse 
prognosis and overall outcomes in breast cancer patients [41–48]. In addition, overexpression of 
SPHK1 in breast cancer cells was reported to increase breast CSCs and the tumorigenicity of tumors 
in nude mice via S1P binding to S1P3 and down-stream stimulation of Notch and p38 MAPK signaling 
[49]. Furthermore, benzyl butyl phthalate, a carcinogen that has been shown to induce SPHK1 
expression through activation of the aryl hydrocarbon receptor (AhR), was recently shown to 
enhance the formation of metastasis-initiating breast CSCs, suggesting a role of SPHK1 in breast CSCs 
[50]. 
Using a kinome-wide shRNA library screen, we previously identified that SPHK1 is required 
for breast cancer cell survival [51]. However, whether SPHK1 is required for the survival of breast 
CSCs remains unknown. Hence, this study sought to investigate whether SPHK1 regulates the 
survival of breast CSCs, the underlying mechanism of this protection, and whether there are any 
substantive differences with its role in non-CSCs. In this regard, we demonstrate herein that SPHK1 
expression is increased in breast CSCs compared with non-CSCs and is involved in regulating the 
survival of breast CSCs and non-CSCs through repression of the tumor suppressor function of 
STAT1. Importantly, selective inhibition of SPHK1 enhances doxorubicin sensitivity in breast CSCs 
and non-CSCs. Overall, our results implicate SPHK1 as a potential target for the treatment of 
refractory breast cancers by targeting both breast CSCs and non-CSCs. 
2. Materials and Methods 
2.1. Cell Lines and Cell Culture 
Human breast cancer cell lines, MCF-7, SKBR3, MDA-MB-468 ,and HCC38, were obtained from 
American Type Culture Collection (ATCC, Manassas, VA, USA). Parental cells were cultured in 
RPMI-1640 media containing 10% fetal bovine serum, 100IU/mL penicillin, and 100 µg/mL 
streptomycin (Sigma-Aldrich, USA). To establish the breast CSC culture, parental breast cancer cells 
were seeded at a density of 3  104 cells/well in ultra-low attachment 6 well plates (Corning Inc., 
Corning, NY, USA) in 2mL of MammoCult media (Stem Cell Technologies, Vancouver, Canada) 
supplemented with 4 µg/mL heparin (Stem Cell Technologies, Canada), 0.48 µg/mL hydrocortisone, 
100IU/mL penicillin, and 100µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA), as described 
previously [11,52–56]. After 5 days of culturing, the resulting mammospheres were centrifugated at 
1500 rpm, and the cell pellet was trypsinized with 1× Trypsin EDTA, followed by CD44-APC and 
CD24-PE (BD Biosciences, San Jose, CA, USA) flow cytometry to confirm the enrichment of 
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CD44+/CD24- CSCs [52]. Mammosphere forming efficiency (MFE) was calculated as the ratio of the 
number of mammospheres divided by the initial number of cells plated. 
2.2. Immunoblotting 
Total proteins were extracted using ice-cold lysis buffer (1% NP-40, 1mM DTT, phosphatase 
inhibitor and protease inhibitor cocktail in PBS) followed by immunoblotting [57,58]. Primary 
antibodies against SPHK2, pSTAT1 (Y701), STAT1, IRF9, pSTAT2 (Y690), and STAT2 were purchased 
from Cell Signalling Technologies, USA. Anti-phosphorylated SPHK1 (S225) was obtained from 
ThermoFisher Scientific, Waltham, Massachusetts, USA; anti-SPHK1 from Abcam, USA; and anti-
GAPDH from Santa Cruz Biotechnology, Santa Cruz, CA, USA. All images were captured using the 
ChemiDocTM XRS+ molecular imager (Bio-Rad Laboratories, Hercules, CA, USA).  
2.3. S1P ELISA  
Sphingosine 1 phosphate (S1P) levels were determined using the S1P ELISA kit (MyBioSource, 
San Diego, CA, USA) according to the manufacturer’s instructions. Absorbance readings were 
recorded at 450nm using a SpectraMax® M3 multi-mode microplate reader (Molecular Devices, San 
Jose, CA, USA).  
2.4. Lentivirus Production and Transduction  
The pLKO.1 lentiviral vector (Vec), non-targeting shRNA (NS), and shRNA constructs targeting 
SPHK1 and STAT1 were purchased from Sigma-Aldrich and Dharmacon, respectively. The target 
sequences are shown in Table S4. Lentivirus production and transduction were performed as 
described previously [51,59]. Briefly, packaging plasmids (psPAX2; Addgene plasmid: 12260) and 
envelope plasmids (pMD2.G; Addgene plasmid: 12259) were co-transfected into HEK-293T using 
CalPhos Transfection Kits (Clontech, Mountain View, CA, USA) to produce a high-titer lentiviral 
stock. The lentiviral particles were supplemented with 7.5 g/mL polybrene (Sigma-Aldrich, St. 
Louis, MO, USA) and transduced to adherent cells or mammospheres. The stable pools of cells were 
generated using an shRNA construct targeting STAT1, and puromycin (Sigma-Aldrich, St. Louis, 
MO, USA) selection.  
2.5. Cell Proliferation Assay 
Cell viability was quantified using CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI, USA; generally referred to as the MTS cell viability assay) [60]. Both attached 
cells and mammospheres were seeded in 96 well plates overnight before being exposed to treatment 
for 72 h. CellTiter 96® AQueous One Solution Reagent was added to each well and further incubated 
for 4 h. The MTS tetrazolium compound was bioreduced by viable attached cells or mammospheres 
to form a stable colored formazan product. The absorbance of the resulting formazan was measured 
using a TECAN Infinite F200 96 well plate reader (Tecan Group Ltd.,Männedorf, Switzerland) at 
540nm.  
2.6. Caspase Activation Assay 
The caspase 3/7, 8, and 9 activities were measured using the Caspase-Glo 3/7, Caspase-Glo 8, 
and Caspase-Glo 9 Assay kits (Promega, Madison, WI, USA), respectively, according to the 
manufacturer’s instructions.  
2.7. Proteomic Profiling  
The SPHK1 plasmid was ectopically expressed in HEK293 cells followed by proteomic profiling 
using LC-MS/MS analysis (Supplemental Methods). Processing and protein identification were 
conducted as described previously [61]. Proteins were defined as differentially expressed when 
expression differed by >2.0 fold between control and SPHK1-overexpressing cells and were 
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significant when tested with the Student’s t-test with a cut-off point of p < 0.05. Differentially 
expressed genes were mapped to known molecular pathways using DAVID Functional Annotation 
Bioinformatics Tool v6.8 (https://david.ncifcrf.gov/). 
2.8. ISRE and GAS Luciferase Reporter Assay 
SPHK1 shRNAs were co-transfected with an IFN-stimulated response element (ISRE) or 
gamma-activated sequences (GAS) luciferase reporter (Qiagen, Germantown, MD, USA) using X-
tremeGENE HP DNA transfection reagent (Roche Diagnostics, Indianapolis, IN, USA). ISRE or GAS 
luciferase activities were determined using a SpectraMax® M3 multi-mode microplate reader 
(Molecular Devices, San Jose, CA, USA) at 48 h after transfection. 
2.9. Apoptosis Assay 
Both floating and attached cells were collected and stained with the PE-Annexin V Apoptosis 
Detection Kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s instructions. 
Results were recorded using an FACSCalibur flow cytometer (BD Biosciences, USA) and analyzed 
using CellQuest Pro Software (BD Biosciences, San Jose, CA, USA).  
3. Results 
3.1. The SPHK1-S1P Axis Is Hyperactivated in Breast CSCs 
Both SPHK isoforms, SPHK1 and SPHK2, are reported to be involved in regulating oncogenesis 
in human cancers [62,63]. To investigate whether the SPHK-S1P axis is altered in breast CSCs, we 
evaluated the basal expression levels of SPHK1, phosphorylated SPHK1, and SPHK2 in a panel of 
breast CSCs derived from MCF-7, SKBR3, MDA-MB-468, and HCC38 breast cancer cells. Of note, the 
breast CSCs enriched from the breast cancer cell lines have been previously shown to contain 
functional cancer stem cells with high CD44 and low CD24 expression and retain high tumorigenic 
activity when injected into the mammary fat pad of SCID mice [52–56]. 
As shown in Figure 1A, phosphorylated SPHK1 and total SPHK1 were consistently upregulated 
in all the breast CSCs tested as compared with the parental cells, while the inverse was observed for 
SPHK2, where higher levels of expression were detected in the parental cells compared with breast 
CSCs. These expression patterns, however, were not observed at the mRNA levels, suggesting that 
the upregulation of SPHK1 and downregulation of SPHK2 in breast CSCs are independent of 
transcription activation and might be regulated at the post-transcriptional level, possibly at the level 
of protein stability (Figure S1). 
Similarly, secreted S1P was also significantly elevated in breast CSCs compared to the parental 
cells (Figure 1B), suggesting that the upregulation of SPHK1 alone is sufficient to compensate for the 
downregulation of SPHK2 in the production S1P in breast CSCs. 
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Figure 1. SPHK1 protein and S1P secretion are increased in breast cancer stem cells (CSCs) compared 
to adherent parental cells. (A) SPHK1 and phosphorylated SPHK1 protein expression was 
upregulated, while SPHK2 expression was downregulated in CSCs derived from MCF-7, SKBR3, 
HCC38, and MDA-MB-468 breast cancer cells. (B) S1P secretion was increased in CSC cultures 
compared to their respective parental cells. Bars represent the means ± s.d. of three independent 
experiments. Asterisks (*) indicate statistical significance compared with parental cells (p < 0.01, 
Student’s t-test). 
3.2. Depletion of SPHK1 Inhibits Breast CSCs’ and Non-CSCs’ Survival and Proliferation 
Next, we evaluated whether SPHK1 was involved in regulating the survival and/or proliferation 
of breast CSCs and non-CSCs. We knocked down the expression of endogenous SPHK1 in HCC38 
and MDA-MB-468 parental and CSCs using two independent lentiviral shRNAs followed by 
evaluation of cell proliferation using the MTS assay. As shown in Figure 2A,B and Figure 3A,B, 
efficient knockdown of SPHK1 expression was demonstrated at the protein level for both shRNA 
constructs (SPHK1-si1 and SPHK1-si2) in HCC38 and MDA-MB-468 parental and CSCs. SPHK1 
depletion was accompanied by significant reductions in cell proliferation in both the parental and 
CSCs of HCC38 and MDA-MB-468 (Figures 2C–F and 3C–F). The effects of SPHK1 depletion on cell 
survival were assessed using Annexin V/7-AAD flow cytometry. We observed significant apoptosis 
in SPHK1-depleted parental and CSCs (p < 0.01, Student’s t-test) corroborated by a significant 
induction of caspase 3/7 and 9 activities (p < 0.01, Student’s t-test), but not caspase 8 activity (Figure 
4A–C and Figure S2). These results indicated that SPHK1 is required for breast CSCs’ and non-CSCs’ 
survival and proliferation.  
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Figure 2. Depletion of SPHK1 inhibits HCC38 CSC and non-CSC proliferation. (A,B) Efficient 
depletion of SPHK1 expression was achieved using two independent lentiviral shRNA constructs in 
non-CSC and CSC cultures. Vector (Vec) and non-silencing (NS) controls were included for accurate 
assessments of knockdown efficiency; GAPDH was used as a loading control. (C,D) Morphological 
changes were observed following knockdown of SPHK1 in non-CSC and CSC cultures. (E and F) Cell 
proliferation between 0 and 72 h was significantly reduced in SPHK1-depleted non-CSC and CSC 
cultures. Points represent the means ± s.d. of three independent experiments. Asterisks (*) indicate 
statistical significance compared with non-silencing (NS) control cells (p < 0.01, Student’s t-test). 
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Figure 3. Depletion of SPHK1 inhibits MDA-MB-468 CSCs’ and non-CSCs’ proliferation. (A and B) 
Efficient depletion of SPHK1 expression was achieved using two independent lentiviral shRNA 
constructs in non-CSC and CSC cultures. Vector (Vec) and non-silencing (NS) controls were included 
for accurate assessments of knockdown efficiency; GAPDH was used as a loading control. (C and D) 
Morphological changes were observed following knockdown of SPHK1 in non-CSC and CSC 
cultures. (E and F) Cell proliferation between 0 and 72 h was significantly reduced in SPHK1-depleted 
non-CSC and CSC cultures. Points represent the means ± s.d. of three independent experiments. 
Asterisks (*) indicate statistical significance compared with non-silencing (NS) control cells (p < 0.01, 
Student’s t-test). 
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Figure 4. Depletion of SPHK1 induces cell apoptosis in breast CSC and non-CSC cultures. (A) Efficient 
depletion of SPHK1 expression was achieved using a single lentiviral shRNA construct in HCC38 and 
MDA-MB-468 adherent parental (Par) and CSC cultures. Non-silencing (NS) controls were included 
for accurate assessments of knockdown efficiency; GAPDH was detected as a loading control. (B) The 
proportion of cells undergoing apoptosis was assessed by Annexin V/7-AAD flow cytometry at 72 h 
following SPHK1 knockdown. Note the significant induction of apoptosis in transduced parental and 
CSCs. (C) Depletion of SPHK1 expression activates caspase 3/7 and 9, but not caspase 8. Both parental 
and CSCs were transduced with lentiviral shRNA targeting endogenous SPHK1. Caspase activities 
were determined using the CaspaseGlo assay at 72 h after transduction. Bars represent the means ± 
s.d. of three independent experiments. Asterisks (*) indicate statistical significance compared with 
non-silencing (NS) control cells (p < 0.01, Student’s t-test). 
3.3. Ectopic Expression of SPHK1 Enhances Breast CSCs’ Survival and Mammosphere Forming Efficiency, 
but not Cell Fate Transition 
Given the fact that SPHK1 has been shown to regulate breast CSCs expansion and 
tumorigenicity [49], we tested whether overexpression of SPHK1 enhances mammosphere formation 
and increases the population of CSCs. To test this hypothesis, we generated a panel of isogenic cell 
lines with ectopic expression of SPHK1 in HCC38 and MDA-MB-468 cells. Our results showed that 
overexpression of SPHK1 induced significant cell proliferation and enhanced mammosphere forming 
efficiency (MFE) in both parental and CSCs of HCC38 and MDA-MB-468 (Figure 5 and Figure 6A,B; 
p < 0.01, Student’s t-test). Interestingly, no significant changes in the CD44+/CD24-/low cell population 
in the parental cells overexpressing SPHK1 were observed, suggesting that SPHK1 promotes breast 
CSC survival and mammosphere formation, but does not drive transition [64].  
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Figure 5. Overexpression of SPHK1 promotes cell proliferation in breast CSCs and non-CSCs. SPHK1 
was overexpressed in (A,B) HCC38 and (C,D) MDA-MB-468 parental and CSCs. Cells’ proliferation 
was determined using the MTS assay. Note the increases in cell proliferation in both parental and 
CSCs following SPHK1 overexpression. Points represent the means ± s.d. of three independent 
experiments. Asterisks (*) indicate statistical significance compared with vector (Vec) control cells (p 
< 0.01, Student’s t-test). 
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Figure 6. Overexpression of SPHK1 promotes mammosphere formation, but does not affect the 
proportion of stem-like cells in parental cultures. (A,B) SPHK1 was overexpressed in HCC38 and 
MDA-MB-468 prior to mammosphere formation assays. The number of mammospheres was counted 
for each subline and the mammosphere forming efficiency (MFE) determined as the proportion of 
mammosphere-forming cells relative to the number of single cells seeded. Results are expressed as 
normalized ratios against the MFE of the vector control cells. Representative phase contrast 
microscope images are shown. (C) Overexpression of SPHK1 in parental HCC38 and MDA-MB-468 
has no effect on the proportion of CD44+/CD24low/- cells. Bars represent the means ± s.d. of three 
independent experiments. Asterisks (*) indicate statistical significance compared with vector (Vec) 
control cells (p < 0.01, Student’s t-test). 
3.4. Proteomic Profiling Identifies STAT1 as the Major Target Regulated by SPHK1 
We next investigated the mechanism by which SPHK1 regulates the proliferation and survival 
of breast CSCs and non-CSCs to establish which signaling networks are functional. To define 
potential signaling networks regulated by SPHK1, we conducted a global proteomic analysis using 
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multidimensional protein identification technology (MudPIT) in ectopic SPHK1 overexpressing 
HEK-293 cells (Figure 7A). A total of 35 proteins were found to be upregulated (fold change > 2), 
while 77 were downregulated (Figure 7B and Tables S1 and S2). 
Further functional enrichment analysis using DAVID Functional Annotation Tools revealed that 
expression of SPHK1 is significantly associated with type I and II interferon signaling pathways 
(Figure 7C and Table S3). Indeed, unsupervised clustering of differentially regulated proteins in 
HEK293 cells overexpressing SPHK1 enabled identification of three major clusters of proteins. These 
were: (1) STAT1 and IFN signaling, (2) IGFBP signaling, and (3) homocysteine metabolism. We 
focused our attention on STAT1 and IFN signaling in breast CSC and parental cells because STAT1 
is a negative regulator of proliferation and cell survival [65], and this could account for the function 
of SPHK1 in promoting these cell responses reported herein. 
 
Figure 7. Multidimensional protein identification technology (MudPIT) identifies novel targets of 
SPHK1. (A) SPHK1 was overexpressed in HEK-293 cells. Protein lysates were isolated and subjected 
to MudPIT analyses. As evident from the FLAG-tag immunoblot, virtually all of the detected SPHK1 
is exogenously expressed. (B) A total of 34 proteins were upregulated (more than two-fold,) while 74 
proteins were downregulated. (C) The top 10 most enriched GO terms in proteins deregulated by 
SPHK1 overexpression, determined by DAVID enrichment analysis. Type I and II interferon signaling 
are two of the most significantly perturbed pathways in SPHK1-overexpressing cells. (D) Protein-
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protein interaction network of SPHK1 target proteins. Networks were generated with STRING using 
a confidence threshold of 0.7. 
3.5. Depletion of SPHK1 Induces STAT1 and Activates Type I and II Interferon Signalling 
To dissect the interactions between SPHK1 and IFN signaling and to validate the MudPIT 
findings, the effect of SPHK1 depletion on protein expression of STAT1, pSTAT1 (V701), STAT2, 
pSTAT2 (Y690), and IRF9 was determined in parental and CSCs derived from HCC38 and MDA-MB-
468 cells (Figure 8A). Depletion of SPHK1 resulted in upregulation of STAT1, pSTAT1, and IRF9 in 
both parental and CSCs, while STAT2 and pSTAT2 expression levels remained unchanged.  
Since STAT1 has been shown to play a pivotal role in type I and type II interferon (IFN) signaling 
and possess tumor suppressor activities, particularly in mammary tumor formation [66–68], we 
hypothesized that one mechanism by which SPHK1 might promote breast CSCs’ and non-CSCs’ 
survival is through suppression of STAT1.  
Of note, upon activation, phosphorylated STAT1 is known to interact with STAT2 and IRF9 to 
form the interferon-stimulated gene factor 3 (ISGF3) complex. ISGF3, in turn, binds to IFN-stimulated 
response element (ISRE) sequences to activate classical STAT1 target genes [69]. Alternatively, STAT1 
might also form homodimers that bind to the gamma-activated sequences (GASs) to induce pro-
inflammatory genes’ expression [69].  
To test whether the knockdown of SPHK1 activates STAT1-dependent transcription through 
ISRE or GAS, we co-transfected SPHK1 shRNA together with an ISRE or GAS luciferase reporter into 
parental and CSCs derived from HCC38 and MDA-MB468 cells. As shown in Figure 8B, depletion of 
SPHK1 led to significant activation of ISRE-dependent reporter gene transcription in parental and 
CSC cultures in both cell lines. Similarly, SPHK1 depletion also activated GAS-dependent luciferase 
expression in HCC38 CSCs and in MDA-MB-468 parental and CSCs, while a modest increase in GAS-
dependent reporter activity was observed in HCC38 parental cells.  
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Figure 8. Depletion of SPHK1 induces increased expression of STAT1 and activates type I and type II 
interferon signaling. (A) Depletion of SPHK1 expression in parental and CSCs of HCC38 and MDA-
MB-468 induced expression of total STAT1, pSTAT1, and IRF9. Expression of total STAT2 and 
pSTAT2 was unchanged. (B and C) Knockdown of SPHK1 induced type I and II interferon 
transcriptional activities. HCC38 and MDA-MB-468 parental and CSCs were co-transfected with the 
SPHK1 shRNA IFN-stimulated response element (ISRE) or gamma-activated sequences (GAS) 
luciferase reporter constructs. Luciferase activities were determined at 48 h after transfection. Bars 
represent the means ± s.d. of three independent experiments. Asterisks (*) indicate statistical 
significance compared with non-silencing (NS) control cells (p < 0.01, Student’s t-test). 
3.6. Apoptosis Induced by SPHK1 Depletion Is Mediated through STAT1 
Next, we investigated whether SPHK1 reduces the tumor suppressive function of STAT1. Thus, 
we evaluated the apoptotic effects of SPHK1 depletion in a stable pool of STAT1 knockdown cells 
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using two independent STAT1 shRNAs. As shown in Figures 9 and 10, depletion of STAT1 
significantly rescued the apoptosis induced by the knockdown of SPHK1 expression in both parental 
and CSCs of HCC38 and MDA-MB-468, suggesting that SPHK1 functions to promote the survival of 
breast CSCs and non-CSCs via a STAT1-dependent mechanism. 
 
Figure 9. Apoptosis induced by SPHK1 depletion in HCC38 parental and CSCs is dependent on 
STAT1 function. (A) A stable pool of STAT1 depleted cells was generated by transduction of lentiviral 
shRNA targeting STAT1, followed by brief puromycin selection. Cells were then transfected with 
SPHK1 shRNAs. Immunoblots were performed at 72 h after SPHK1 knockdown. (B) Depletion of 
STAT1 rescued SPHK1 knockdown induced apoptosis. Apoptosis was quantitated using Annexin 
V/7-AAD flow cytometry at 72 h after SPHK1 knockdown. Bars represent the means ± s.d. of three 
independent experiments. Asterisks (*) indicate statistical significance compared with non-silencing 
(NS) control cells (p < 0.01, Student’s t-test). 
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Figure 10. Apoptosis induced by SPHK1 depletion in MDA-MB-468 parental and CSC is dependent 
on STAT1 function. (A) A stable pool of STAT1 depleted cells was generated by transduction of 
lentiviral shRNA targeting STAT1 followed by brief puromycin selection. Cells were then transfected 
with SPHK1 shRNAs. Immunoblots were performed at 72 h after SPHK1 knockdown. (B) Depletion 
of STAT1 rescued SPHK1 knockdown induced apoptosis. Apoptosis was quantitated using Annexin 
V/7-AAD flow cytometry at 72 h after SPHK1 knockdown. Bars represent the means ± s.d. of three 
independent experiments. Asterisks (*) indicate statistical significance compared with non-silencing 
(NS) control cells (p < 0.01, Student’s t-test). 
3.7. SPHK1 Inhibitors Enhance Doxorubicin Sensitivity in Basal-Like Breast CSCs and Non-CSCs. 
Since our results showed that SPHK1 plays functional roles in regulating the survival of breast 
CSCs and non-CSCs and given that recent studies have highlighted the potential of utilizing agents 
that manipulate sphingolipid metabolism to augment the chemotherapeutic efficacy in hematological 
malignancies [70], we sought to investigate whether inhibitors targeting SPHK1 and the sphingolipid 
rheostat might exert anti-proliferative effects in breast CSCs and non-CSCs. 
A total of four inhibitors targeting SPHK were used and tested in combination with doxorubicin. 
FTY720 inhibits SPHK1, and its phosphorylated equivalent modulates S1P receptors [71,72]; PF543 is 
a nM potent selective inhibitor of SPHK1 [73]; SK1-II acts as dual SPHK1/SPHK2 inhibitor; and 
ABC294640 is a selective M potent SPHK2 inhibitor [74], but in androgen independent prostate 
cancer cells can also induce the proteasomal degradation of SPHK1 [75].  
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Consistent with previous studies, the breast CSCs were inherently more resistant to doxorubicin 
compared to the parental cells (two-fold in HCC38 and 14-fold in MDA-MB-468; Table 1) [52,56]. 
However, we found that the HCC38 CSCs were more sensitive to PF543, but resistant to SK1-II, as 
compared with the parental cells, while FTY720 and ABC294640 showed equal potency against both 
the parental and CSCs in HCC38 cells. The high EC50 values determined for PF543 suggested that at 
higher concentrations of PF543, there might be “off-target” effects. In addition, the effect of 
ABC294640 is unlikely attributable to SPHK2 in CSCs, as it is absent in these cells. In contrast, the 
MDA-MB-468 CSCs were found to be slightly more resistant (1.4- to our-fold) to all the SPHK 
inhibitors as compared with the parental cells (Figure 11). 
Next, we investigated whether SPHK inhibitors exhibit synergism with conventional 
chemotherapy, specifically doxorubicin, in eradicating both breast CSCs and non-CSCs. Our results 
indicated that combinations of FTY720 or PF543 synergized with doxorubicin in both parental and 
CSC cultures of basal-like HCC38 and MDA-MB-468 cells. A very low concentrations of PF543 (0.78 
M) was used to induce synergism with doxorubicin in CSC cultures of HCC38 cells, and this is a 
concentration at which SPHK1 is selectively inhibited. ABC294640 exhibited selective synergism with 
doxorubicin in the parental cells, but not CSCs of HCC38 and MDA-MB-468, consistent with the lack 
of expression of SPHK2 in CSCs (Figures 12 and 13). In contrast, the combination of doxorubicin and 
SK1-II exerted antagonistic effect in both parental and CSC cultures of HCC38 and MDA-MB-468. In 
this case, it is interesting to note that SK1-II can also induce the polyubiquitination of 
dihydroceramide desaturase, and these forms are linked with pro-survival p38 MAPK/JNK and XBP-
1s pathways in HEK293T cells [76].  
Taken together, our results suggested that inhibitors targeting SPHK1, but not SPHK2, 
potentiated doxorubicin-induced cytotoxicity in the basal-like breast CSCs and non-CSCs. 
Table 1. EC50 values of doxorubicin and SPHK inhibitors in parental and breast CSCs. 
Drugs HCC38  MDA-MB-468 
Parental CSCs  Parental CSCs 
Doxorubicin (µM)  0.20 ± 0.02 0.59 ± 0.14  0.15 ± 0.04 2.22 ± 1.03 
FTY720 (µM) 9.50 ± 0.13 9.04 ± 0.33  5.30 ± 0.14 16.29 ± 0.81 
PF543 (µM) 72.86 ± 4.68 33.89 ± 3.67  21.55 ± 7.67 85.98 ± 15.70 
ABC294640 (µM) 65.20 ± 6.42 60.85 ± 5.10  22.57 ± 1.02 31.56 ± 3.01 
SK1-II (µM) 29.70 ± 11.56 41.36 ± 4.73  7.58 ± 0.52 15.72 ± 5.21 
 
Figure 11. Selective growth inhibitory activities of SPHK inhibitors in parental and breast CSCs. 
HCC38 and MDA-MB-468 parental and CSCs were treated with different concentrations of FTY720, 
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PF543, ABC294640, and SK1-II for 72 h, and cell viability was determined by the MTT or MTS assay. 
Points represent the mean ± s.d. of three independent experiments. Asterisks (*) indicate statistical 
significance compared with parental cells (p < 0.05, Student’s t-test). 
 
Figure 12. Combination effects of SPHK inhibitors and doxorubicin (Dox) against HCC38 parental 
and CSCs. Cells were treated with a sublethal concentration of SPHK inhibitors in combination with 
doxorubicin for 72 h. Cell viability was determined by the MTT or MTS assay. The dashed line 
represents the cell viability following treatment of the indicated concentrations of FTY720, PF543, 
ABC294640, and SK1-II. Points represent the mean ± s.d. of three independent experiments. Asterisks 
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(*) indicate statistical significance compared with cells treated with either doxorubicin or SPHK 
inhibitors alone (p < 0.05, Student’s t-test). 
. 
Figure 13. Combination effects of SPHK inhibitors and doxorubicin (Dox) against MDA-MB-468 
parental and CSCs. Cells were treated with a sub-lethal concentration of SPHK inhibitors in 
combination with doxorubicin for 72 h. Cell viability was determined by the MTT or MTS assay. The 
dashed line represents the cell viability following treatment of the indicated concentrations of FTY720, 
PF543, ABC294640, and SK1-II. Points represent the mean ± s.d. of three independent experiments. 
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Asterisks (*) indicate statistical significance compared with cells treated with either doxorubicin or 
SPHK inhibitors alone (p < 0.05, Student’s t-test). 
4. Discussion 
In this study, we demonstrated that the SPHK1-S1P axis is hyper-activated in breast CSCs and 
promotes cell survival in both breast CSCs and non-CSCs by suppressing STAT1 expression. We 
further demonstrated that depletion of SPHK1 led to de-repression of STAT1 and induced type I and 
type II interferon signaling. Importantly, selective inhibition of SPHK1 (but not SPHK2) enhanced 
doxorubicin sensitivity in breast CSCs and non-CSCs. Collectively our findings suggested a novel 
role for SPHK1 in attenuating STAT1-mediated IFN signaling, and therapies targeting this signaling 
axis may be beneficial to breast cancer patients.  
Overexpression of SPHK1 is associated with tumorigenic cell behavior that involves promoting 
cell growth, migration, and inhibiting apoptosis [24–26,38–41,44]. Recent studies also indicated that 
SPHK1-S1P may play a role in regulating CSCs populations in breast cancer models. Stimulation of 
SPHK1/S1P/S1P3 by environmental carcinogens promoted CSC-induced tumor metastasis in vivo; 
while knockdown of S1P3 reduced the CSC population in MCF-7 cells [50]. Similarly, the presence of 
S1P induces Notch signaling and augments mammosphere-forming capacity in breast CSCs, and S1P3 
is highly expressed in ALDH-positive cells derived from breast cancer patients, suggesting that the 
SPHK1/S1P/S1P3 axis is important for the maintenance of stem-like features [49]. 
Although the mechanism by which SPHK1 suppresses STAT1 phosphorylation and 
downregulates total STAT1 levels remains to be further investigated, several pieces of evidence 
suggest that S1P might play an essential role. Indeed, recent studies have shown that activation of 
S1P1 and S1P2 by S1P suppresses IFN and STAT1 activity [77,78]. In addition, S1P binding to S1P1 has 
also been shown to promote STAT3 activation [30,79,80], which is pro-tumorigenic in breast cancer 
[81]. Thus, a reduction in S1P levels with SPHK1 knockdown might inhibit these pathways and 
relieve inhibition of the STAT1/IFN pathway. 
Important evidence also demonstrates the tumor suppressor properties of STAT1 in mammary 
tumorigenesis [66–68,82,83]. For instance, STAT1 activation has been shown to regulate the 
expression of cell cycle regulators transcriptionally (upregulates p21WAF1 and p27KIP1 and 
downregulates cyclins A and E, CDK2). It also enhances the function of pro-apoptotic proteins 
(upregulates BAK and inhibits transcription of BCL2 and BCL-XL) and death-receptors and their 
ligands (induces TNF, FAS, TRAIL) [82,83]. Recently, STAT1 has also been shown to modulate cell 
death by direct protein–protein interaction with p53 following DNA damage [84,85]. 
Our results indicated that the selective SPHK1 inhibitor, PF543, synergized with doxorubicin in 
both parental and CSC cultures of basal-like HCC38 and MDA-MB-468 cells, indicating that SPHK1 
and its regulation of STAT1 might be of therapeutic utility. Of note, DNA damage and doxorubicin 
have been previously shown to downregulate SPHK1 protein expression and activity via 
proteasomal degradation of the enzyme [86,87]. 
The SPHK2 inhibitor, ABC294640, exhibited selective synergism with doxorubicin in the 
parental cells, but not CSCs of HCC38 and MDA-MB-468 cells. The role of SPHK2 in cancer is more 
controversial, with evidence showing both oncogenic and anti-cancer effects. Overexpression of 
SPHK2 was reported to suppress cell growth and induce apoptosis by sequestration of BCL2 by its 
BH3 domain [88], while siRNA-mediated loss of SPHK2 from cancer cells produced a strong anti-
cancer effects [89]. In addition, the treatment of early stage and advanced prostate cancer cells with 
the selective SPHK2 inhibitor, ABC294640, induces a reduction in Myc and androgen receptor (AR) 
expression, and this is associated with significant inhibition of growth, proliferation, and cell cycle 
progression [90]. Furthermore, knockout of the Sphk2 gene reduces leukemia development in a 
mouse model of acute lymphoblastic leukemia (ALL), and pharmacologic inhibition extends survival 
of mice in xenograft models of human disease [76]. SPHK2 is also implicated in multiple myeloma 
[91] and the SPHK2 inhibitor, (R)-FTY720 methyl ether (ROMe), induces the autophagic death of T-
ALL cell lines [91]. 
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Despite the important roles of sphingolipid metabolism in cancer biology, only very few agents 
targeting this pathway have reached clinical trials relating to cancer. These include safingol (L-threo-
dihydrosphingosine), a PKC inhibitor (Phase 1; NCT01553071 and NCT00084812); ABC294640, a 
SPHK2 inhibitor (Phase I/II; NCT01488513, NCT02229981, NCT02757326, NCT02939807, 
NCT03377179, and NCT03414489); sonepcizumab (ASONEP), an S1P-specific monoclonal antibody 
(Phase I/II; NCT00661414 and NCT01762033); and Fingolimod, an S1P receptor antagonist (Phase I; 
NCT02490930). Given the synergistic effects of PF543 and doxorubicin on breast CSCs and non-CSCs 
in our study, it was proposed that neoadjuvant treatment with SPHK1 inhibitors with doxorubicin 
would reduce both CSCs and non-CSCs and thereby potentially improve therapeutic response in 
breast cancer patients.  
5. Conclusions 
In conclusion, we demonstrated that SPHK1 is required for breast CSCs’ and non-CSCs’ survival 
through suppression of the tumor suppressor function of STAT1. Targeting SPHK1 using PF543 
significantly synergized the anti-proliferative effects of doxorubicin. Hence, targeting SPHK1-S1P-
STAT1 could trigger multifaceted anti-tumor responses and may be a promising approach 
warranting further development.  
Supplementary Materials: The following are available online at www.mdpi.com/2073-4409/9/4/886/s1. Figure 
S1: mRNA Expression of SPHK1 and SPHK2 in breast CSCs and non-CSCs, Table S1: List of proteins that were 
upregulated in HEK-293 cells following ectopic expression of SPHK1 (log2 ratio of SPHK1/vector > 2), Table S2: 
List of proteins that were downregulated in HEK-293 cells following ectopic expression of SPHK1 (log2 ratio of 
SPHK1/vector < -2), Table S3: List of pathways that were significantly enriched in HEK-293 cells following 
ectopic expression of SPHK1 (p < 0.05), Table S4: shRNA target sequences for SPHK1 and STAT1, and Table S5: 
Forward and reverse primer sequences for quantitative RT-PCR, Supplemental Methods: Proteomic profiling 
using LC-MS/MS analysis. 
Author Contributions: Conceptualization, C.O.L., N.J.P., and S.P.; methodology, F.F.L.C., C.W.M., and N.E.D.; 
investigation, L.W.H., F.F.L.C., Z.Y.Y., H.H.C., C.W.M., W.M.L., V.J.R., and N.E.D.; formal analysis, L.W.H., 
F.F.L.C., C.W.M., V.J.R., and N.E.D.; writing, original draft preparation, C.O.L., L.W.H., F.F.L.C., and C.W.M.; 
writing, review and editing, C.O.L, N.J.P., and S.P.; supervision, C.O.L., F.F.L.C., and C.W.M.; project 
administration, C.O.L.; funding acquisition, C.O.L. All authors have read and agreed to the published version 
of the manuscript. 
Funding: This research was funded by the Ministry of Higher Education, Malaysia, Grant Numbers 
FRGS/1/2016/SKK08/IMU/01/1 and ERGS/1/2013/SKK01/IMU/02/1. 
Conflicts of Interest: The authors declare no conflict of interest.  
References 
1. Batlle, E.; Clevers, H. Cancer stem cells revisited. Nat. Med. 2017, 23, 1124–1134, doi:10.1038/nm.4409. 
2. Barbato, L.; Bocchetti, M.; Di Biase, A.; Regad, T. Cancer Stem Cells and Targeting Strategies. Cells 2019, 8, 
doi:10.3390/cells8080926. 
3. Marotta, L.L.; Almendro, V.; Marusyk, A.; Shipitsin, M.; Schemme, J.; Walker, S.R.; Bloushtain-Qimron, N.; 
Kim, J.J.; Choudhury, S.A.; Maruyama, R.; et al. The JAK2/STAT3 signaling pathway is required for growth 
of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Investig. 2011, 121, 2723–2735, 
doi:10.1172/JCI44745. 
4. Kim, S.Y.; Kang, J.W.; Song, X.; Kim, B.K.; Yoo, Y.D.; Kwon, Y.T.; Lee, Y.J. Role of the IL-6-JAK1-STAT3-
Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell. Signal. 2013, 25, 
961–969, doi:10.1016/j.cellsig.2013.01.007. 
5. de Sousa, E.M.F.; Vermeulen, L. Wnt Signaling in Cancer Stem Cell Biology. Cancers 2016, 8, 
doi:10.3390/cancers8070060. 
6. Jang, G.B.; Hong, I.S.; Kim, R.J.; Lee, S.Y.; Park, S.J.; Lee, E.S.; Park, J.H.; Yun, C.H.; Chung, J.U.; Lee, K.J.; 
et al. Wnt/beta-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast 
Cancer Stem-like Cells. Cancer Res. 2015, 75, 1691–1702, doi:10.1158/0008-5472.CAN-14-2041. 
Cells 2020, 9, 886 21 of 25 
 
7. Jang, G.B.; Kim, J.Y.; Cho, S.D.; Park, K.S.; Jung, J.Y.; Lee, H.Y.; Hong, I.S.; Nam, J.S. Blockade of Wnt/beta-
catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci. Rep. 2015, 5, 
12465, doi:10.1038/srep12465. 
8. Farnie, G.; Clarke, R.B. Mammary stem cells and breast cancer--role of Notch signalling. Stem Cell Rev. 2007, 
3, 169–175. 
9. D’Angelo, R.C.; Ouzounova, M.; Davis, A.; Choi, D.; Tchuenkam, S.M.; Kim, G.; Luther, T.; Quraishi, A.A.; 
Senbabaoglu, Y.; Conley, S.J.; et al. Notch reporter activity in breast cancer cell lines identifies a subset of 
cells with stem cell activity. Mol. Cancer Ther. 2015, 14, 779–787, doi:10.1158/1535-7163.MCT-14-0228. 
10. Zhao, D.; Mo, Y.; Li, M.T.; Zou, S.W.; Cheng, Z.L.; Sun, Y.P.; Xiong, Y.; Guan, K.L.; Lei, Q.Y. NOTCH-
induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J. Clin. Investig. 
2014, 124, 5453–5465, doi:10.1172/JCI76611. 
11. Suman, S.; Das, T.P.; Damodaran, C. Silencing NOTCH signaling causes growth arrest in both breast cancer 
stem cells and breast cancer cells. Br. J. Cancer 2013, 109, 2587–2596, doi:10.1038/bjc.2013.642. 
12. Takebe, N.; Harris, P.J.; Warren, R.Q.; Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and 
Hedgehog pathways. Nat. Reviews. Clin. Oncol. 2011, 8, 97–106, doi:10.1038/nrclinonc.2010.196. 
13. Chang, W.H.; Lai, A.G. Aberrations in Notch-Hedgehog signalling reveal cancer stem cells harbouring 
conserved oncogenic properties associated with hypoxia and immunoevasion. Br. J. Cancer 2019, 
10.1038/s41416-019-0572-9, doi:10.1038/s41416-019-0572-9. 
14. Cochrane, C.R.; Szczepny, A.; Watkins, D.N.; Cain, J.E. Hedgehog Signaling in the Maintenance of Cancer 
Stem Cells. Cancers 2015, 7, 1554–1585, doi:10.3390/cancers7030851. 
15. Sari, I.N.; Phi, L.T.H.; Jun, N.; Wijaya, Y.T.; Lee, S.; Kwon, H.Y. Hedgehog Signaling in Cancer: A 
Prospective Therapeutic Target for Eradicating Cancer Stem Cells. Cells 2018, 7, doi:10.3390/cells7110208. 
16. Takebe, N.; Miele, L.; Harris, P.J.; Jeong, W.; Bando, H.; Kahn, M.; Yang, S.X.; Ivy, S.P. Targeting Notch, 
Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat. Reviews. Clin. Oncol. 2015, 12, 445–
464, doi:10.1038/nrclinonc.2015.61. 
17. Choi, H.S.; Kim, J.H.; Kim, S.L.; Lee, D.S. Disruption of the NF-kappaB/IL-8 Signaling Axis by Sulconazole 
Inhibits Human Breast Cancer Stem Cell Formation. Cells 2019, 8, doi:10.3390/cells8091007. 
18. Shostak, K.; Chariot, A. NF-kappaB, stem cells and breast cancer: The links get stronger. Breast Cancer Res.: 
Bcr 2011, 13, 214, doi:10.1186/bcr2886. 
19. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J.B.; Zhang, Y. NF-kappaB pathway inhibitors preferentially 
inhibit breast cancer stem-like cells. Breast Cancer Res. Treat. 2008, 111, 419–427, doi:10.1007/s10549-007-
9798-y. 
20. Liu, S.; Wicha, M.S. Targeting breast cancer stem cells. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2010, 28, 
4006–4012, doi:10.1200/JCO.2009.27.5388. 
21. Clarke, M.F. Clinical and Therapeutic Implications of Cancer Stem Cells. New Engl. J. Med. 2019, 380, 2237–
2245, doi:10.1056/NEJMra1804280. 
22. Scioli, M.G.; Storti, G.; D’Amico, F.; Gentile, P.; Fabbri, G.; Cervelli, V.; Orlandi, A. The Role of Breast Cancer 
Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy. Cancers 
2019, 11, doi:10.3390/cancers11071021. 
23. Park, S.Y.; Choi, J.H.; Nam, J.S. Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. Cancers 2019, 
11, doi:10.3390/cancers11070965. 
24. Pyne, N.J.; El Buri, A.; Adams, D.R.; Pyne, S. Sphingosine 1-phosphate and cancer. Adv. Biol. Regul. 2018, 
68, 97–106, doi:10.1016/j.jbior.2017.09.006. 
25. Pyne, S.; Pyne, N.J. Translational aspects of sphingosine 1-phosphate biology. Trends Mol. Med. 2011, 17, 
463–472, doi:10.1016/j.molmed.2011.03.002. 
26. Pyne, S.; Adams, D.R.; Pyne, N.J. Sphingosine 1-phosphate and sphingosine kinases in health and disease: 
Recent advances. Prog. Lipid Res. 2016, 62, 93–106, doi:10.1016/j.plipres.2016.03.001. 
27. Pyne, N.J.; McNaughton, M.; Boomkamp, S.; MacRitchie, N.; Evangelisti, C.; Martelli, A.M.; Jiang, H.R.; 
Ubhi, S.; Pyne, S. Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer 
and inflammation. Adv. Biol. Regul. 2016, 60, 151–159, doi:10.1016/j.jbior.2015.09.001. 
28. Fang, Z.; Pyne, S.; Pyne, N.J. Ceramide and sphingosine 1-phosphate in adipose dysfunction. Prog. Lipid 
Res. 2019, 74, 145–159, doi:10.1016/j.plipres.2019.04.001. 
29. Pyne, N.J.; Ohotski, J.; Bittman, R.; Pyne, S. The role of sphingosine 1-phosphate in inflammation and 
cancer. Adv. Biol. Regul. 2014, 54, 121–129, doi:10.1016/j.jbior.2013.08.005. 
Cells 2020, 9, 886 22 of 25 
 
30. Pyne, N.J.; Pyne, S. Sphingosine 1-phosphate is a missing link between chronic inflammation and colon 
cancer. Cancer Cell 2013, 23, 5–7, doi:10.1016/j.ccr.2012.12.005. 
31. Pyne, S.; Chapman, J.; Steele, L.; Pyne, N.J. Sphingomyelin-derived lipids differentially regulate the 
extracellular signal-regulated kinase 2 (ERK-2) and c-Jun N-terminal kinase (JNK) signal cascades in airway 
smooth muscle. Eur. J. Biochem. 1996, 237, 819–826, doi:10.1111/j.1432-1033.1996.0819p.x. 
32. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P.G.; Coso, O.A.; Gutkind, S.; Spiegel, S. Suppression of 
ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381, 800–803, 
doi:10.1038/381800a0. 
33. Newton, J.; Lima, S.; Maceyka, M.; Spiegel, S. Revisiting the sphingolipid rheostat: Evolving concepts in 
cancer therapy. Exp. Cell Res. 2015, 333, 195–200, doi:10.1016/j.yexcr.2015.02.025. 
34. Pyne, S.; Edwards, J.; Ohotski, J.; Pyne, N.J. Sphingosine 1-phosphate receptors and sphingosine kinase 1: 
Novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front. Oncol. 2012, 
2, 168, doi:10.3389/fonc.2012.00168. 
35. Pyne, N.J.; Tonelli, F.; Lim, K.G.; Long, J.S.; Edwards, J.; Pyne, S. Sphingosine 1-phosphate signalling in 
cancer. Biochem. Soc. Trans. 2012, 40, 94–100, doi:10.1042/BST20110602. 
36. Pyne, N.J.; Tonelli, F.; Lim, K.G.; Long, J.; Edwards, J.; Pyne, S. Targeting sphingosine kinase 1 in cancer. 
Adv. Biol. Regul. 2012, 52, 31–38, doi:10.1016/j.advenzreg.2011.07.001. 
37. Pyne, S.; Bittman, R.; Pyne, N.J. Sphingosine kinase inhibitors and cancer: Seeking the golden sword of 
Hercules. Cancer Res. 2011, 71, 6576–6582, doi:10.1158/0008-5472.CAN-11-2364. 
38. Song, L.; Xiong, H.; Li, J.; Liao, W.; Wang, L.; Wu, J.; Li, M. Sphingosine kinase-1 enhances resistance to 
apoptosis through activation of PI3K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clin. 
Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011, 17, 1839–1849, doi:10.1158/1078-0432.CCR-10-0720. 
39. Acharya, S.; Yao, J.; Li, P.; Zhang, C.; Lowery, F.J.; Zhang, Q.; Guo, H.; Qu, J.; Yang, F.; Wistuba, II; et al. 
Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2019, 79, 
4211–4226, doi:10.1158/0008-5472.CAN-18-3803. 
40. Pyne, N.J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Reviews. Cancer 2010, 10, 489–503, 
doi:10.1038/nrc2875. 
41. Long, J.S.; Edwards, J.; Watson, C.; Tovey, S.; Mair, K.M.; Schiff, R.; Natarajan, V.; Pyne, N.J.; Pyne, S. 
Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents 
formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive 
breast cancer cells. Mol. Cell. Biol. 2010, 30, 3827–3841, doi:10.1128/MCB.01133-09. 
42. Datta, A.; Loo, S.Y.; Huang, B.; Wong, L.; Tan, S.S.; Tan, T.Z.; Lee, S.C.; Thiery, J.P.; Lim, Y.C.; Yong, W.P.; 
et al. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget 2014, 
5, 5920–5933, doi:10.18632/oncotarget.1874. 
43. Ruckhaberle, E.; Rody, A.; Engels, K.; Gaetje, R.; von Minckwitz, G.; Schiffmann, S.; Grosch, S.; Geisslinger, 
G.; Holtrich, U.; Karn, T.; et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic 
significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 2008, 112, 41–52, 
doi:10.1007/s10549-007-9836-9. 
44. Zhu, Y.J.; You, H.; Tan, J.X.; Li, F.; Qiu, Z.; Li, H.Z.; Huang, H.Y.; Zheng, K.; Ren, G.S. Overexpression of 
sphingosine kinase 1 is predictive of poor prognosis in human breast cancer. Oncol. Lett. 2017, 14, 63–72, 
doi:10.3892/ol.2017.6134. 
45. Maiti, A.; Takabe, K.; Hait, N.C. Metastatic triple-negative breast cancer is dependent on SphKs/S1P 
signaling for growth and survival. Cell. Signal. 2017, 32, 85–92, doi:10.1016/j.cellsig.2017.01.021. 
46. Watson, C.; Long, J.S.; Orange, C.; Tannahill, C.L.; Mallon, E.; McGlynn, L.M.; Pyne, S.; Pyne, N.J.; Edwards, 
J. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and 
extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen 
receptor-positive breast cancer patients. Am. J. Pathol. 2010, 177, 2205–2215, doi:10.2353/ajpath.2010.100220. 
47. Ohotski, J.; Edwards, J.; Elsberger, B.; Watson, C.; Orange, C.; Mallon, E.; Pyne, S.; Pyne, N.J. Identification 
of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate 
receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast 
cancer. Int. J. Cancer 2013, 132, 605–616, doi:10.1002/ijc.27692. 
48. Ohotski, J.; Long, J.S.; Orange, C.; Elsberger, B.; Mallon, E.; Doughty, J.; Pyne, S.; Pyne, N.J.; Edwards, J. 
Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in 
oestrogen receptor-negative breast cancer. Br. J. Cancer 2012, 106, 1453–1459, doi:10.1038/bjc.2012.98. 
Cells 2020, 9, 886 23 of 25 
 
49. Hirata, N.; Yamada, S.; Shoda, T.; Kurihara, M.; Sekino, Y.; Kanda, Y. Sphingosine-1-phosphate promotes 
expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat. Commun. 2014, 5, 
4806, doi:10.1038/ncomms5806. 
50. Wang, Y.C.; Tsai, C.F.; Chuang, H.L.; Chang, Y.C.; Chen, H.S.; Lee, J.N.; Tsai, E.M. Benzyl butyl phthalate 
promotes breast cancer stem cell expansion via SPHK1/S1P/S1PR3 signaling. Oncotarget 2016, 7, 29563–
29576, doi:10.18632/oncotarget.9007. 
51. Tiong, K.H.; Tan, B.S.; Choo, H.L.; Chung, F.F.; Hii, L.W.; Tan, S.H.; Khor, N.T.; Wong, S.F.; See, S.J.; Tan, 
Y.F.; et al. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine 
enhance breast cancer cells survival. Oncotarget 2016, 7, 57633–57650, doi:10.18632/oncotarget.9328. 
52. Soo, J.S.; Ng, C.H.; Tan, S.H.; Malik, R.A.; Teh, Y.C.; Tan, B.S.; Ho, G.F.; See, M.H.; Taib, N.A.; Yip, C.H.; et 
al. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy 
through impairing intracellular ATP production and DNA repair in breast cancer stem cells. Apoptosis: Int. 
J. Program. Cell Death 2015, 20, 1373–1387, doi:10.1007/s10495-015-1158-5. 
53. Fillmore, C.M.; Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give 
rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res.: Bcr 2008, 10, R25, 
doi:10.1186/bcr1982. 
54. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Wicinski, J.; Cervera, N.; Finetti, P.; Hur, M.H.; Diebel, M.E.; 
Monville, F.; Dutcher, J.; et al. Breast cancer cell lines contain functional cancer stem cells with metastatic 
capacity and a distinct molecular signature. Cancer Res. 2009, 69, 1302–1313, doi:10.1158/0008-5472.CAN-
08-2741. 
55. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; 
Daidone, M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor 
cell properties. Cancer Res. 2005, 65, 5506–5511, doi:10.1158/0008-5472.CAN-05-0626. 
56. Hii, L.W.; Chung, F.F.; Soo, J.S.; Tan, B.S.; Mai, C.W.; Leong, C.O. Histone deacetylase (HDAC) inhibitors 
and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells 
simultaneously. Breast Cancer Res. Treat. 2019, 10.1007/s10549-019-05504-5, doi:10.1007/s10549-019-05504-5. 
57. Soo, H.C.; Chung, F.F.; Lim, K.H.; Yap, V.A.; Bradshaw, T.D.; Hii, L.W.; Tan, S.H.; See, S.J.; Tan, Y.F.; Leong, 
C.O.; et al. Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through 
Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway. PLoS ONE 2017, 12, e0170551, 
doi:10.1371/journal.pone.0170551. 
58. Er, J.L.; Goh, P.N.; Lee, C.Y.; Tan, Y.J.; Hii, L.W.; Mai, C.W.; Chung, F.F.; Leong, C.O. Identification of 
inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal 
adenocarcinoma (PDAC). Apoptosis : Int. J. Program. Cell Death 2018, 23, 343–355, doi:10.1007/s10495-018-
1459-6. 
59. Chung, F.F.; Tan, P.F.; Raja, V.J.; Tan, B.S.; Lim, K.H.; Kam, T.S.; Hii, L.W.; Tan, S.H.; See, S.J.; Tan, Y.F.; et 
al. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 
(SF3B1). Sci. Rep. 2017, 7, 42504, doi:10.1038/srep42504. 
60. Stone, E.L.; Citossi, F.; Singh, R.; Kaur, B.; Gaskell, M.; Farmer, P.B.; Monks, A.; Hose, C.; Stevens, M.F.; 
Leong, C.O.; et al. Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate 
with activity; synthesis of 5F203 hydrogels for local delivery. Bioorganic Med. Chem. 2015, 23, 6891–6899, 
doi:10.1016/j.bmc.2015.09.052. 
61. Huang, F.K.; Zhang, G.; Lawlor, K.; Nazarian, A.; Philip, J.; Tempst, P.; Dephoure, N.; Neubert, T.A. Deep 
Coverage of Global Protein Expression and Phosphorylation in Breast Tumor Cell Lines Using TMT 10-
plex Isobaric Labeling. J. Proteome Res. 2017, 16, 1121–1132, doi:10.1021/acs.jproteome.6b00374. 
62. Spiegel, S.; Milstien, S. Functions of the multifaceted family of sphingosine kinases and some close relatives. 
J. Biol. Chem. 2007, 282, 2125–2129, doi:10.1074/jbc.R600028200. 
63. Okada, T.; Ding, G.; Sonoda, H.; Kajimoto, T.; Haga, Y.; Khosrowbeygi, A.; Gao, S.; Miwa, N.; Jahangeer, 
S.; Nakamura, S. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent 
regulation of cell proliferation and apoptosis. J. Biol. Chem. 2005, 280, 36318–36325, 
doi:10.1074/jbc.M504507200. 
64. Blick, T.; Hugo, H.; Widodo, E.; Waltham, M.; Pinto, C.; Mani, S.A.; Weinberg, R.A.; Neve, R.M.; Lenburg, 
M.E.; Thompson, E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel 
the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 
2010, 15, 235–252, doi:10.1007/s10911-010-9175-z. 
Cells 2020, 9, 886 24 of 25 
 
65. Meissl, K.; Macho-Maschler, S.; Muller, M.; Strobl, B. The good and the bad faces of STAT1 in solid tumours. 
Cytokine 2017, 89, 12–20, doi:10.1016/j.cyto.2015.11.011. 
66. Chan, S.R.; Vermi, W.; Luo, J.; Lucini, L.; Rickert, C.; Fowler, A.M.; Lonardi, S.; Arthur, C.; Young, L.J.; 
Levy, D.E.; et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal 
mammary carcinomas. Breast Cancer Res. : Bcr 2012, 14, R16, doi:10.1186/bcr3100. 
67. Klover, P.J.; Muller, W.J.; Robinson, G.W.; Pfeiffer, R.M.; Yamaji, D.; Hennighausen, L. Loss of STAT1 from 
mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 2010, 12, 899–
905, doi:10.1593/neo.10716. 
68. Raven, J.F.; Williams, V.; Wang, S.; Tremblay, M.L.; Muller, W.J.; Durbin, J.E.; Koromilas, A.E. Stat1 is a 
suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. 
Cell Cycle 2011, 10, 794–804, doi:10.4161/cc.10.5.14956. 
69. Mogensen, T.H. IRF and STAT Transcription Factors From Basic Biology to Roles in Infection, Protective 
Immunity, and Primary Immunodeficiencies. Front. Immunol. 2018, 9, 3047, doi:10.3389/fimmu.2018.03047. 
70. Lewis, A.C.; Wallington-Beddoe, C.T.; Powell, J.A.; Pitson, S.M. Targeting sphingolipid metabolism as an 
approach for combination therapies in haematological malignancies. Cell Death Discov. 2018, 4, 4, 
doi:10.1038/s41420-018-0075-0. 
71. Tonelli, F.; Lim, K.G.; Loveridge, C.; Long, J.; Pitson, S.M.; Tigyi, G.; Bittman, R.; Pyne, S.; Pyne, N.J. FTY720 
and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation 
in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. 
Cell. Signal. 2010, 22, 1536–1542, doi:10.1016/j.cellsig.2010.05.022. 
72. Hla, T.; Brinkmann, V. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor 
modulation. Neurology 2011, 76, S3-8, doi:10.1212/WNL.0b013e31820d5ec1. 
73. Schnute, M.E.; McReynolds, M.D.; Kasten, T.; Yates, M.; Jerome, G.; Rains, J.W.; Hall, T.; Chrencik, J.; Kraus, 
M.; Cronin, C.N.; et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of 
sphingosine kinase-1. Biochem. J. 2012, 444, 79–88, doi:10.1042/BJ20111929. 
74. French, K.J.; Zhuang, Y.; Maines, L.W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J.J.; Green, C.L.; Keller, 
S.N.; Smith, C.D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine 
kinase-2. J. Pharmacol. Exp. Ther. 2010, 333, 129–139, doi:10.1124/jpet.109.163444. 
75. McNaughton, M.; Pitman, M.; Pitson, S.M.; Pyne, N.J.; Pyne, S. Proteasomal degradation of sphingosine 
kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or 
ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget 
2016, 7, 16663–16675, doi:10.18632/oncotarget.7693. 
76. Alsanafi, M.; Kelly, S.L.; Jubair, K.; McNaughton, M.; Tate, R.J.; Merrill, A.H., Jr.; Pyne, S.; Pyne, N.J. Native 
and Polyubiquitinated Forms of Dihydroceramide Desaturase Are Differentially Linked to Human 
Embryonic Kidney Cell Survival. Mol. Cell. Biol. 2018, 38, doi:10.1128/MCB.00222–18. 
77. Teijaro, J.R.; Studer, S.; Leaf, N.; Kiosses, W.B.; Nguyen, N.; Matsuki, K.; Negishi, H.; Taniguchi, T.; 
Oldstone, M.B.; Rosen, H. S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell 
interferon-alpha autoamplification. Proc. Natl. Acad. Sci. USA 2016, 113, 1351–1356, 
doi:10.1073/pnas.1525356113. 
78. Yester, J.W.; Bryan, L.; Waters, M.R.; Mierzenski, B.; Biswas, D.D.; Gupta, A.S.; Bhardwaj, R.; Surace, M.J.; 
Eltit, J.M.; Milstien, S., et al. Sphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 
5 via c-Fos-dependent suppression of IFN-beta amplification loop. Faseb J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 
2015, 29, 4853–4865, doi:10.1096/fj.15-275180. 
79. Murakami, M.; Ito, H.; Hagiwara, K.; Kobayashi, M.; Hoshikawa, A.; Takagi, A.; Kojima, T.; Tamiya-
Koizumi, K.; Sobue, S.; Ichihara, M.; et al. Sphingosine kinase 1/S1P pathway involvement in the GDNF-
induced GAP43 transcription. J. Cell. Biochem. 2011, 112, 3449–3458, doi:10.1002/jcb.23275. 
80. Liang, J.; Nagahashi, M.; Kim, E.Y.; Harikumar, K.B.; Yamada, A.; Huang, W.C.; Hait, N.C.; Allegood, J.C.; 
Price, M.M.; Avni, D.; et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal 
inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23, 107–120, 
doi:10.1016/j.ccr.2012.11.013. 
81. Haricharan, S.; Li, Y. STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. 
Mol. Cell. Endocrinol. 2014, 382, 560–569, doi:10.1016/j.mce.2013.03.014. 
82. Bailey, S.G.; Cragg, M.S.; Townsend, P.A. Role of STAT1 in the breast. Jak-Stat. 2012, 1, 197–199, 
doi:10.4161/jkst.20967. 
Cells 2020, 9, 886 25 of 25 
 
83. Koromilas, A.E.; Sexl, V. The tumor suppressor function of STAT1 in breast cancer. Jak-Stat. 2013, 2, e23353, 
doi:10.4161/jkst.23353. 
84. Baran-Marszak, F.; Feuillard, J.; Najjar, I.; Le Clorennec, C.; Bechet, J.M.; Dusanter-Fourt, I.; Bornkamm, 
G.W.; Raphael, M.; Fagard, R. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell 
cycle arrest and apoptosis in human B cells. Blood 2004, 104, 2475–2483, doi:10.1182/blood-2003-10-3508. 
85. Townsend, P.A.; Scarabelli, T.M.; Davidson, S.M.; Knight, R.A.; Latchman, D.S.; Stephanou, A. STAT-1 
interacts with p53 to enhance DNA damage-induced apoptosis. J. Biol. Chem. 2004, 279, 5811–5820, 
doi:10.1074/jbc.M302637200. 
86. Powell, J.A.; Pitman, M.R.; Zebol, J.R.; Moretti, P.A.B.; Neubauer, H.A.; Davies, L.T.; Lewis, A.C.; Dagley, 
L.F.; Webb, A.I.; Costabile, M.; et al. Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes 
proteasomal degradation of sphingosine kinase 1. Biochem. J. 2019, 476, 3211–3226, 
doi:10.1042/BCJ20190245. 
87. Taha, T.A.; Osta, W.; Kozhaya, L.; Bielawski, J.; Johnson, K.R.; Gillanders, W.E.; Dbaibo, G.S.; Hannun, Y.A.; 
Obeid, L.M. Down-regulation of sphingosine kinase-1 by DNA damage: Dependence on proteases and p53. 
J. Biol. Chem. 2004, 279, 20546–20554, doi:10.1074/jbc.M401259200. 
88. Maceyka, M.; Sankala, H.; Hait, N.C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.S.; 
Merrill, A.H., Jr.; et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in 
sphingolipid metabolism. J. Biol. Chem. 2005, 280, 37118–37129, doi:10.1074/jbc.M502207200. 
89. Gao, P.; Smith, C.D. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol. 
Cancer Res.: Mcr 2011, 9, 1509–1519, doi:10.1158/1541-7786.MCR-11-0336. 
90. Schrecengost, R.S.; Keller, S.N.; Schiewer, M.J.; Knudsen, K.E.; Smith, C.D. Downregulation of Critical 
Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Mol. Cancer 
Res.: Mcr 2015, 13, 1591–1601, doi:10.1158/1541-7786.MCR-14-0626. 
91. Wallington-Beddoe, C.T.; Bennett, M.K.; Vandyke, K.; Davies, L.; Zebol, J.R.; Moretti, P.A.B.; Pitman, M.R.; 
Hewett, D.R.; Zannettino, A.C.W.; Pitson, S.M. Sphingosine kinase 2 inhibition synergises with bortezomib 
to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget 2017, 8, 43602–43616, 
doi:10.18632/oncotarget.17115. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
